中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

82 records (took 0.028 seconds)

    Antigen specific T cell therapy
    31.
    发明申请
    Antigen specific T cell therapy 审中-公开
    抗原特异性T细胞治疗

    公开(公告)号：US20050238626A1

    公开(公告)日：2005-10-27

    申请号：US11071785

    申请日：2005-03-02

    Applicant: Lili Yang ,  David Baltimore

    Inventor： Lili Yang ,  David Baltimore

    IPC: A61K39/00 ,  A61K48/00 ,  C12N5/08

    CPC classification number: A61K39/0011 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158

    Abstract: Provided are methods for generating immune cells of the desired type and specificity in a host. The methods may be used to treat a disease or disorder, such as a tumor in a patient. Target cells, preferably hematopoietic stem cells such as primary bone marrow cells are transfected with a polynucleotide encoding a T cell receptor with the desired specificity. The transfected cells are then transferred to the host where they develop into mature, functional immune cells. The source of the T cell receptor can determine the stem cell's fate. Thus transfecting stem cells with TCRs from cytotoxic cells will lead to the generation of cytotoxic T cells in the host, while TCRs from helper cells will produce helper cells. Both arms of T cell immunity can be generated simultaneously in a host. Additionally, the immune response to the desired antigen can be further stimulated by immunizing the host with the antigen.

    Abstract translation: 提供了在宿主中产生所需类型和特异性的免疫细胞的方法。 该方法可用于治疗疾病或病症，例如患者中的肿瘤。 用编码具有所需特异性的T细胞受体的多核苷酸转染靶细胞，优选造血干细胞如原代骨髓细胞。 然后将转染的细胞转移到宿主，在那里它们发育成成熟的功能性免疫细胞。 T细胞受体的来源可以确定干细胞的命运。 因此，用来自细胞毒性细胞的TCR转染干细胞将导致宿主中产生细胞毒性T细胞，而来自辅助细胞的TCR将产生辅助细胞。 T细胞免疫的两个臂可以在宿主中同时产生。 另外，可以通过用抗原免疫宿主来进一步刺激对所需抗原的免疫应答。

    Methods and compositions for inhibiting cell growth and proliferation
    32.
    发明申请
    Methods and compositions for inhibiting cell growth and proliferation 审中-公开
    抑制细胞生长和增殖的方法和组合物

    公开(公告)号：US20050158311A1

    公开(公告)日：2005-07-21

    申请号：US10972078

    申请日：2004-10-22

    Applicant: Wange Lu ,  David Baltimore

    Inventor： Wange Lu ,  David Baltimore

    IPC: A61K38/16 ,  A61K38/17 ,  A61K39/395 ,  A61K48/00 ,  C12N20060101 ,  G01N33/53 ,  G01N33/567

    CPC classification number: A61K38/16

    Abstract: Compositions, including, for example, soluble Ryk polypeptides and/or agents that selectively bind Ryk, are provided. Methods of using such agents or compositions also are provided, including, for example, methods of using such compositions to inhibit proliferation of a cell exhibiting, or predisposed to exhibiting, unregulated growth. In addition, methods of ameliorating a cancer in a subject are provided.

    Abstract translation: 提供了组合物，包括例如可溶性Ryk多肽和/或选择性结合Ryk的试剂。 还提供了使用这些试剂或组合物的方法，包括例如使用这些组合物抑制显示或倾向于显示未调节生长的细胞增殖的方法。 此外，提供了改善受试者中的癌症的方法。

    Compositions for inducing cell growth and differentiation and methods of using same
    33.
    发明申请
    Compositions for inducing cell growth and differentiation and methods of using same 审中-公开
    用于诱导细胞生长和分化的组合物及其使用方法

    公开(公告)号：US20050153887A1

    公开(公告)日：2005-07-14

    申请号：US10972073

    申请日：2004-10-22

    Applicant: Wange Lu ,  David Baltimore

    Inventor： Wange Lu ,  David Baltimore

    IPC: A61K38/16 ,  A61K38/17 ,  A61K39/395 ,  A61K48/00 ,  C12N20060101 ,  G01N33/53 ,  G01N33/567

    CPC classification number: A61K38/16

    Abstract: Compositions, including, for example, soluble Ryk polypeptides and Wnt polypeptides, that induce cell growth and/or differentiation, including, for example, neurite outgrowth and hematopoietic cell proliferation and differentiation, are provided. Methods of using such compositions also are provided, including, for example, methods of using such compositions to induce neurite outgrowth (e.g., in a subject having a neuronal disorder). In addition, methods to identify agents that alter Ryk mediated signal transduction in a cell are provided.

    Abstract translation: 提供了组合物，包括例如诱导细胞生长和/或分化的可溶性Ryk多肽和Wnt多肽，包括例如神经突向外生长和造血细胞增殖和分化。 还提供了使用这些组合物的方法，包括例如使用这些组合物诱导神经突生长的方法（例如，在具有神经元病症的受试者中）。 此外，提供了鉴定在细胞中改变Ryk介导的信号转导的药剂的方法。

    Method for determining lymphocyte distribution and trafficking in mammals using imaging
    36.
    发明授权
    Method for determining lymphocyte distribution and trafficking in mammals using imaging 失效
    使用成像确定哺乳动物淋巴细胞分布和贩运的方法

    公开(公告)号：US06146614A

    公开(公告)日：2000-11-14

    申请号：US886578

    申请日：1997-07-01

    Applicant: Robert H. Rubin ,  Alan J. Fischman ,  David Baltimore

    Inventor： Robert H. Rubin ,  Alan J. Fischman ,  David Baltimore

    IPC: A61K49/04 ,  A61K49/18 ,  A61K51/10 ,  A61K51/12 ,  A61B5/055

    CPC classification number: A61K51/1027 ,  A61K49/04 ,  A61K49/1896 ,  A61K51/1203

    Abstract: Methods for determining lymphocyte distribution and trafficking in a mammal are described. Either a labeled ligand capable of interacting specifically with the lymphocytes of the mammal is administered to the mammal so that the labeled ligand interacts in vivo with the lymphocytes, resulting in labeled lymphocytes, or, the labeled ligand is contacted with the lymphocytes in vitro so that the labeled ligand interacts with the lymphocytes resulting in labeled lymphocytes, and these labeled lymphocytes are administered to the mammal. The distribution or trafficking of the labeled lymphocytes in the mammal is determined by imaging. Methods for diagnosing the degree of progression of a disease in a mammal by determining the mammal's lymphocyte distribution or trafficking pattern, for monitoring the response to a therapy in mammal having a disease, for evaluating the ability of an agent to alter the distribution or trafficking of lymphocytes, and for identifying an agent useful for treating a mammal having a disease, are also described.

    Abstract translation: 描述了确定哺乳动物淋巴细胞分布和运输的方法。 向哺乳动物施用能够与哺乳动物的淋巴细胞相互作用的标记配体，使得标记的配体在体内与淋巴细胞相互作用，导致标记的淋巴细胞，或者标记的配体在体外与淋巴细胞接触，使得 标记的配体与淋巴细胞相互作用，导致标记的淋巴细胞，并且将这些标记的淋巴细胞施用于哺乳动物。 通过成像确定哺乳动物中标记的淋巴细胞的分布或运输。 用于通过确定哺乳动物的淋巴细胞分布或贩运模式来诊断哺乳动物疾病进展程度的方法，用于监测具有疾病的哺乳动物患有对具有疾病的哺乳动物的治疗的反应，用于评估药剂改变分布或贩运的能力 还描述了用于鉴定可用于治疗患有疾病的哺乳动物的药剂的淋巴细胞。

    Methods for the prognosis and monitoring of AIDS
    38.
    发明授权
    Methods for the prognosis and monitoring of AIDS 失效
    预防和监测艾滋病的方法

    公开(公告)号：US5674680A

    公开(公告)日：1997-10-07

    申请号：US189237

    申请日：1994-01-31

    Applicant: Kalle M. Saksela ,  David Baltimore

    Inventor： Kalle M. Saksela ,  David Baltimore

    IPC: C12Q1/70 ,  C07H21/04 ,  C12P19/34 ,  C12Q1/68

    CPC classification number: C12Q1/703

    Abstract: This invention relates to the prognosis of outcome of infection with the human immunodeficiency virus (HIV). In particular, the present invention concerns monitoring individuals who are at risk for developing acquired immunodeficiency syndrome (AIDS), and individuals who are undergoing therapy for AIDS. The method for estimating the risk of the onset of a clinical event associated with infection with HIV broadly comprises evaluating the rate of HIV replication in peripheral blood cells from an individual suspected of suffering from HIV infection. More particularly, the method comprises determining the level of expression of HIV messenger RNA (mRNA) in peripheral blood cells of an asymptomatic individual. High level expression of HIV mRNA indicates a high likelihood of onset of symptoms of AIDS, and low level expression or determination of no detectable expression indicates a low likelihood of onset of symptoms of AIDS. In a specific embodiment, the level of HIV-1 mRNA, specifically multiply spliced (MS) and unspliced (US) HIV mRNA, is detected in peripheral blood cells from HIV-infected individuals, and the detection of high levels of HIV mRNA is predictive of the onset of clinical symptoms associated with disease progression, including the diagnosis of AIDS, a decrease in the number of CD4+ cells to below 500 CD4+ cells per mm.sup.3, and other clinical events. According to the invention, the onset of clinical AIDS generally occurs within about 2 years of the determination of high level expression of HIV mRNA, and the onset of clinical symptoms generally does not occur for at least about 5 years after the determination of no detectable expression of HIV mRNA.

    Abstract translation: 本发明涉及人类免疫缺陷病毒（HIV）感染结果的预后。 特别地，本发明涉及监测处于发展中的免疫机能丧失综合征（AIDS）风险的个体以及正在接受AIDS治疗的个体。 用于估计与HIV感染相关的临床事件发生风险的方法广泛地包括评估来自怀疑患有HIV感染的个体的外周血细胞中HIV复制的速率。 更具体地，该方法包括确定无症状个体的外周血细胞中HIV信使RNA（mRNA）的表达水平。 HIV mRNA的高水平表达表明发生AIDS症状的可能性很高，低水平表达或无可检测表达的测定表明艾滋病症状发生的可能性很低。 在一个具体的实施方案中，在来自HIV感染个体的外​​周血细胞中检测到HIV-1 mRNA的水平，特异性多重剪接（MS）和未剪接（US）HIV mRNA），并且检测到高水平的HIV mRNA是预测的 与疾病进展相关的临床症状的发病，包括艾滋病的诊断，CD4 +细胞数量减少到每毫米3毫米以下CD4 +细胞至少500个以及其他临床事件。 根据本发明，临床艾滋病的发病通常发生在测定HIV mRNA的高水平表达的约2年内，临床症状的发作通常在确定无可检测的表达后至少约5年不发生 的HIV mRNA。

Patent Agency Ranking